Sphera Funds Management LTD. acquired a new stake in shares of GlaxoSmithKline PLC (NYSE:GSK) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 450,000 shares of the pharmaceutical company’s stock, valued at approximately $19,404,000. GlaxoSmithKline PLC accounts for about 3.3% of Sphera Funds Management LTD.’s portfolio, making the stock its 4th largest position.

Other institutional investors also recently made changes to their positions in the company. Arete Wealth Advisors LLC boosted its position in shares of GlaxoSmithKline PLC by 11.5% in the first quarter. Arete Wealth Advisors LLC now owns 11,828 shares of the pharmaceutical company’s stock valued at $499,000 after buying an additional 1,218 shares during the last quarter. Greenleaf Trust acquired a new position in GlaxoSmithKline PLC during the first quarter worth approximately $466,000. Parsons Capital Management Inc. RI boosted its position in GlaxoSmithKline PLC by 5.4% in the first quarter. Parsons Capital Management Inc. RI now owns 5,842 shares of the pharmaceutical company’s stock worth $246,000 after buying an additional 300 shares during the last quarter. PARK CIRCLE Co boosted its position in GlaxoSmithKline PLC by 26.7% in the first quarter. PARK CIRCLE Co now owns 44,600 shares of the pharmaceutical company’s stock worth $1,880,000 after buying an additional 9,400 shares during the last quarter. Finally, Capital Insight Partners LLC boosted its position in GlaxoSmithKline PLC by 49.1% in the first quarter. Capital Insight Partners LLC now owns 58,822 shares of the pharmaceutical company’s stock worth $2,480,000 after buying an additional 19,371 shares during the last quarter. Institutional investors own 9.28% of the company’s stock.

GlaxoSmithKline PLC (NYSE:GSK) traded down 0.07% during midday trading on Friday, hitting $40.20. 2,974,256 shares of the stock were exchanged. GlaxoSmithKline PLC has a 1-year low of $37.20 and a 1-year high of $44.53. The firm’s 50-day moving average price is $40.36 and its 200 day moving average price is $41.83. The firm has a market capitalization of $98.25 billion, a P/E ratio of 39.96 and a beta of 1.03.

GlaxoSmithKline PLC (NYSE:GSK) last announced its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 EPS for the quarter, beating the Zacks’ consensus estimate of $0.68 by $0.02. The company had revenue of $9.36 billion for the quarter, compared to analysts’ expectations of $9.52 billion. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. Analysts expect that GlaxoSmithKline PLC will post $2.85 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be paid a dividend of $0.491 per share. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 dividend on an annualized basis and a dividend yield of 4.89%. The ex-dividend date is Wednesday, August 9th. GlaxoSmithKline PLC’s dividend payout ratio is presently 197.00%.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/02/sphera-funds-management-ltd-acquires-shares-of-450000-glaxosmithkline-plc-gsk.html.

A number of equities analysts recently commented on GSK shares. J P Morgan Chase & Co reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Thursday, July 13th. Zacks Investment Research upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 price target for the company in a report on Tuesday, July 18th. BidaskClub upgraded GlaxoSmithKline PLC from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. Berenberg Bank upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a report on Friday, May 26th. Finally, Argus reiterated a “buy” rating and set a $50.00 price target on shares of GlaxoSmithKline PLC in a report on Thursday. Two analysts have rated the stock with a sell rating, eight have given a hold rating and ten have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $46.00.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Stock Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related stocks with our FREE daily email newsletter.